
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Treace Medical Concepts Inc (TMCI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TMCI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $8.35
1 Year Target Price $8.35
2 | Strong Buy |
0 | Buy |
5 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.11% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 439.05M USD | Price to earnings Ratio - | 1Y Target Price 8.35 |
Price to earnings Ratio - | 1Y Target Price 8.35 | ||
Volume (30-day avg) 7 | Beta 0.68 | 52 Weeks Range 4.54 - 10.79 | Updated Date 08/15/2025 |
52 Weeks Range 4.54 - 10.79 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.29 | Actual -0.28 |
Profitability
Profit Margin -23.01% | Operating Margin (TTM) -35.82% |
Management Effectiveness
Return on Assets (TTM) -13.83% | Return on Equity (TTM) -46.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 439858225 | Price to Sales(TTM) 2.05 |
Enterprise Value 439858225 | Price to Sales(TTM) 2.05 | ||
Enterprise Value to Revenue 2.06 | Enterprise Value to EBITDA -40.95 | Shares Outstanding 63173100 | Shares Floating 47366578 |
Shares Outstanding 63173100 | Shares Floating 47366578 | ||
Percent Insiders 25.64 | Percent Institutions 61.05 |
Upturn AI SWOT
Treace Medical Concepts Inc
Company Overview
History and Background
Treace Medical Concepts, Inc. was founded in 2014. The company focuses on the surgical treatment of bunions and related deformities of the foot. They pioneered the Lapiplasty procedure.
Core Business Areas
- Bunion Correction: Develops, manufactures, and markets the Lapiplasty System, a surgical procedure for correcting bunions.
Leadership and Structure
John T. Treace is the CEO and founder. The company operates with a structure typical of a medical device company, with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Lapiplasty System: A patented surgical system for 3D bunion correction. Treace is estimated to have around 25% of the surgical bunion correction market. Competitors include Stryker (SYK), Wright Medical (now part of Stryker), and smaller players offering traditional osteotomy techniques. Revenue from this product accounts for the vast majority of Treace's total revenue.
Market Dynamics
Industry Overview
The orthopedic device market is experiencing growth, particularly in foot and ankle procedures. The market is driven by an aging population and increased demand for minimally invasive surgical options.
Positioning
Treace Medical Concepts is positioned as an innovator in the bunion correction space with its Lapiplasty system. Its competitive advantage lies in the patented technology and perceived benefits over traditional bunion surgeries, such as faster recovery times.
Total Addressable Market (TAM)
The estimated TAM for bunion correction procedures is around $5 billion. Treace is positioned to capture a significant portion of this TAM with increased adoption of Lapiplasty.
Upturn SWOT Analysis
Strengths
- Patented Lapiplasty technology
- Strong clinical data supporting Lapiplasty
- Focus on a specific market segment (bunion correction)
- Growing adoption among surgeons
- Strong sales growth
Weaknesses
- Reliance on a single product (Lapiplasty)
- Relatively small company size
- Requires surgeon training for Lapiplasty procedure
- Limited brand recognition compared to larger orthopedic companies
Opportunities
- Expand adoption of Lapiplasty into more markets
- Develop new products for related foot and ankle conditions
- Acquire complementary technologies or companies
- Increase insurance coverage for Lapiplasty
- Penetrate international markets
Threats
- Competition from established orthopedic companies
- Changes in reimbursement policies
- Product liability lawsuits
- Slower-than-expected adoption of Lapiplasty
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- SYK
- BSX
- JNJ
Competitive Landscape
Treace's competitive advantage lies in its specialized focus on bunion correction and its patented Lapiplasty system. However, it faces competition from larger, more diversified orthopedic companies.
Growth Trajectory and Initiatives
Historical Growth: Treace has experienced rapid revenue growth in recent years, driven by increased adoption of Lapiplasty.
Future Projections: Analysts project continued revenue growth for Treace, although profitability may take several years to achieve.
Recent Initiatives: Treace has focused on expanding its sales force, increasing surgeon training programs, and publishing clinical studies supporting Lapiplasty.
Summary
Treace Medical Concepts shows good progress with their Lapiplasty system but must remain focused on sales growth and manage the competition of larger companies. Insurance coverage is important as well as international market penetration. Current losses are an ongoing concern. Positive clinical data can improve adoption.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Treace Medical Concepts Inc
Exchange NASDAQ | Headquaters Ponte Vedra, FL, United States | ||
IPO Launch date 2021-04-23 | Founder, Chairman & CEO Mr. John T. Treace | ||
Sector Healthcare | Industry Medical Devices | Full time employees 477 | Website https://www.treace.com |
Full time employees 477 | Website https://www.treace.com |
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot. It serves physicians, surgeons, ambulatory surgery centers and hospitals related to the surgical management of bunion and related midfoot deformities. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.